Insider Selling: Anne Reiser Sells 3,000 Shares of ResMed Stock (RMD)
ResMed (NYSE:RMD) Insider Anne Reiser unloaded 3,000 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $53.37, for a total value of $160,110.00. Following the transaction, the insider now directly owns 66,524 shares in the company, valued at approximately $3,550,386. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
ResMed (NYSE:RMD) traded up 0.78% during mid-day trading on Wednesday, hitting $53.30. The stock had a trading volume of 876,176 shares. ResMed has a 52 week low of $41.52 and a 52 week high of $57.34. The stock’s 50-day moving average is $51.0 and its 200-day moving average is $48.. The company has a market cap of $7.471 billion and a P/E ratio of 22.13.
ResMed (NYSE:RMD) last announced its earnings results on Thursday, July 31st. The company reported $0.64 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.66 by $0.02. The company had revenue of $415.20 million for the quarter, compared to the consensus estimate of $433.42 million. During the same quarter in the previous year, the company posted $0.62 earnings per share. The company’s revenue for the quarter was up .1% on a year-over-year basis. On average, analysts predict that ResMed will post $2.59 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Thursday, September 18th. Stockholders of record on Thursday, August 21st will be paid a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 2.10%. The ex-dividend date is Tuesday, August 19th. This is a boost from ResMed’s previous quarterly dividend of $0.25.
A number of analysts have recently weighed in on RMD shares. Analysts at Zacks reiterated a “neutral” rating on shares of ResMed in a research note on Friday, August 22nd. They now have a $54.00 price target on the stock. Separately, analysts at Piper Jaffray cut their price target on shares of ResMed from $55.00 to $53.00 in a research note on Friday, August 1st. Finally, analysts at Canaccord Genuity cut their price target on shares of ResMed from $43.00 to $39.00 in a research note on Friday, August 1st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $45.90.
ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.